ReviewCytotherapy2009
Mesenchymal stem cells in hematopoietic stem cell transplantation.
Review in Cytotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study.Oncotarget · 2016Trial
- Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.Clinical journal of the American Society of Nephrology : CJASN · 2011Trial
- Extracellular vesicles from mesenchymal stromal cells primed with synthetic toll-like receptor 4 agonists treat hematopoietic acute radiation syndrome.Stem cells translational medicine · 2026Article
- MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance.Regenerative therapy · 2025Review
- Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.Regenerative therapy · 2025Review
- Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation.Stem cell research & therapy · 2025Review
- Simultaneous Co-transplantation for Highly Efficient Cell Therapy.Current stem cell research & therapy · 2025Review
- Stem cell-based therapy for systemic lupus erythematous.Journal of translational autoimmunity · 2024Review
- Efficient and cost-effective differentiation of induced neural crest cells from induced pluripotent stem cells using laminin 211.Regenerative therapy · 2024Article
- Comparison of the mesodermal differentiation potential between embryonic stem cells and scalable induced pluripotent stem cells.Journal of the Chinese Medical Association : JCMA · 2024Article
- Differentiation ability of hematopoietic stem cells and mesenchymal stem cells isolated from human peripheral blood.Frontiers in cell and developmental biology · 2024Article
- Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche.Exploration of targeted anti-tumor therapy · 2024Review
- Stem cell-based therapy for systemic sclerosis.Rheumatology advances in practice · 2023Review
- A comparative study of mouse bone marrow mesenchymal stem cells isolated using three easy-to-perform approaches.FEBS open bio · 2022Article
- Induction of functional xeno-free MSCs from human iPSCs via a neural crest cell lineage.NPJ Regenerative medicine · 2022Article
- How mesenchymal stem cell cotransplantation with hematopoietic stem cells can improve engraftment in animal models.World journal of stem cells · 2022Article
- Defects in Long-Term APC Repopulation Ability of Adult Human Bone Marrow Hematopoietic Stem Cells (HSCs) Compared with Fetal Liver HSCs.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Engineered Tissue Models to Replicate Dynamic Interactions within the Hematopoietic Stem Cell Niche.Advanced healthcare materials · 2022Review
- Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective.Bioengineering (Basel, Switzerland) · 2022Review
- The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.Frontiers in immunology · 2022Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mesenchymal stromal/stem cells (MSC) of bone marrow (BM) origin not only provide the supportive microenvironmental niche for hematopoietic stem cells (HSC) but are capable of differentiating into various cell types of mesenchymal origin, such as bone, fat and cartilage. In vitro and in vivo data suggest that MSC have low inherent immunogenicity, modulate/suppress immunologic responses through interactions with immune cells, and home to damaged tissues to participate in regeneration processes through their diverse biologic properties. MSC derived from BM are being evaluated for a wide range of clinical applications, including disorders as diverse as myocardial infarction and newly diagnosed diabetes mellitus type 1. However, their use in HSC transplantation, either for enhancement of hematopoietic engraftment or for treatment/prevention of graft-versus-host disease, is far ahead of other indications. Ease of isolation and ex vivo expansion of MSC, combined with their intriguing immunomodulatory properties and their impressive record of safety in a wide variety of clinical trials, make these cells promising candidates for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.